JP2019059786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019059786A5 JP2019059786A5 JP2018241924A JP2018241924A JP2019059786A5 JP 2019059786 A5 JP2019059786 A5 JP 2019059786A5 JP 2018241924 A JP2018241924 A JP 2018241924A JP 2018241924 A JP2018241924 A JP 2018241924A JP 2019059786 A5 JP2019059786 A5 JP 2019059786A5
- Authority
- JP
- Japan
- Prior art keywords
- sema4d
- antibody
- composition
- seq
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056102 CD100 antigen Proteins 0.000 claims 11
- 102100027744 Semaphorin-4D Human genes 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000001130 astrocyte Anatomy 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000003399 chemotactic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 102100034384 Plexin-B1 Human genes 0.000 claims 1
- 101710100559 Plexin-B1 Proteins 0.000 claims 1
- 102100034383 Plexin-B2 Human genes 0.000 claims 1
- 101710100551 Plexin-B2 Proteins 0.000 claims 1
- 208000037875 astrocytosis Diseases 0.000 claims 1
- 230000007341 astrogliosis Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 102000002022 plexin Human genes 0.000 claims 1
- 108050009312 plexin Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Claims (11)
- それを必要とする対象におけるアストログリオーシスを防止するまたは低下させることにおいて使用するための、セマフォリン-4D（SEMA4D）に特異的に結合する単離された抗体またはその抗原結合断片の有効量を含む薬学的組成物。
- 傷害を有するまたは有すると推測される対象において、アストロサイト突起の退縮および傷害領域へのオリゴデンドロサイト前駆細胞（OPC）の走化性移動を防止することにおいて使用するための、セマフォリン4D（SEMA4D）に特異的に結合する単離された抗体またはその抗原結合断片の有効量を含む薬学的組成物。
- 対象におけるOPCのアストロサイトによって媒介される栄養サポートの維持または回復に使用するための、セマフォリン4D（SEMA4D）に特異的に結合する単離された抗体またはその抗原結合断片の有効量を含む薬学的組成物であって、該抗体またはその抗原結合断片は、傷害を有するまたは有すると推測される対象おける、アストロサイト突起の退縮および傷害領域へのOPCの走化性移動を防止する、薬学的組成物。
- 抗体またはその断片が、SEMA4DのSEMA4D受容体またはその一部分との相互作用を阻害する、請求項1〜3のいずれか一項記載の薬学的組成物。
- 前記受容体が、プレキシン-B1、プレキシン-B2、およびCD72からなる群より選択される、請求項4記載の組成物。
- 抗体またはその断片が、SEMA4Dによって媒介されるプレキシン-B1シグナル伝達を阻害する、請求項1〜3のいずれか一項記載の組成物。
- 抗体またはその断片は、SEQ ID NO: 6、7、および8をそれぞれ含むVHCDR1〜3を含む可変重鎖（VH）、ならびにSEQ ID NO: 14、15、および16をそれぞれ含むVLCDR1〜3を含む可変軽鎖（VL）を含む、請求項1〜3のいずれか一項記載の組成物。
- VHおよびVLが、それぞれ、SEQ ID NO:9およびSEQ ID NO:17またはSEQ ID NO:10およびSEQ ID NO:18を含む、請求項7記載の組成物。
- 抗体またはその断片が、アストロサイトによって媒介される血液脳関門の完全性の維持をモジュレートする、請求項1記載の薬学的組成物。
- 単離された抗体またはその抗原結合断片が、重鎖可変領域（VH）アミノ酸配列SEQ ID NO: 9および軽鎖可変領域（VL）アミノ酸配列SEQ ID NO: 17を含む参照モノクローナル抗体と同一のSEMA4Dエピトープに結合する、請求項1〜8のいずれか一項記載の組成物。
- 単離された抗体またはその断片が、重鎖可変領域（VH）アミノ酸配列SEQ ID NO: 9および軽鎖可変領域（VL）アミノ酸配列SEQ ID NO: 17を含む参照モノクローナル抗体のSEMA4Dへの結合を競合的に阻害する、請求項10記載の組成物。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893814P | 2013-10-21 | 2013-10-21 | |
| US61/893,814 | 2013-10-21 | ||
| US201461979384P | 2014-04-14 | 2014-04-14 | |
| US61/979,384 | 2014-04-14 | ||
| US201462012805P | 2014-06-16 | 2014-06-16 | |
| US62/012,805 | 2014-06-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524999A Division JP6461944B2 (ja) | 2013-10-21 | 2014-10-21 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019059786A JP2019059786A (ja) | 2019-04-18 |
| JP2019059786A5 true JP2019059786A5 (ja) | 2020-01-09 |
| JP6875363B2 JP6875363B2 (ja) | 2021-05-26 |
Family
ID=52826380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524999A Active JP6461944B2 (ja) | 2013-10-21 | 2014-10-21 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
| JP2018241924A Active JP6875363B2 (ja) | 2013-10-21 | 2018-12-26 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524999A Active JP6461944B2 (ja) | 2013-10-21 | 2014-10-21 | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9598495B2 (ja) |
| EP (2) | EP3639853B1 (ja) |
| JP (2) | JP6461944B2 (ja) |
| KR (4) | KR20210118246A (ja) |
| CN (2) | CN106029093B (ja) |
| AU (3) | AU2014340210B2 (ja) |
| BR (1) | BR112016009047B1 (ja) |
| CA (2) | CA2927841C (ja) |
| DK (1) | DK3060252T3 (ja) |
| EA (1) | EA033072B1 (ja) |
| ES (1) | ES2773961T3 (ja) |
| IL (3) | IL275720B (ja) |
| MX (2) | MX374708B (ja) |
| NZ (1) | NZ630892A (ja) |
| PL (1) | PL3060252T3 (ja) |
| PT (1) | PT3060252T (ja) |
| SG (2) | SG11201603167YA (ja) |
| WO (1) | WO2015061330A1 (ja) |
| ZA (1) | ZA201602686B (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2427212T (pt) | 2009-05-08 | 2017-11-20 | Vaccinex Inc | Anticorpos anti-cd100 e métodos para utilização dos mesmos |
| WO2013055922A1 (en) | 2011-10-11 | 2013-04-18 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US10626163B2 (en) * | 2013-01-25 | 2020-04-21 | Brandeis University | Methods of modulating GABAergic inhibitory synapse formation and function |
| JP6611709B2 (ja) | 2013-06-25 | 2019-11-27 | バクシネックス インコーポレーティッド | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| SG11201808554TA (en) | 2016-04-22 | 2018-11-29 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| US20190383836A1 (en) * | 2017-02-22 | 2019-12-19 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| DK3600419T5 (en) * | 2017-03-20 | 2024-05-27 | Vaccinex Inc | Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent |
| EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | HUMAN ANTI-SEMAPHORINE 4D ANTIBODY |
| CN109410218B (zh) * | 2018-10-08 | 2020-08-11 | 百度在线网络技术（北京）有限公司 | 用于生成车辆损伤信息的方法和装置 |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| MX2022016188A (es) | 2020-06-25 | 2023-10-30 | Vaccinex Inc | Uso de moléculas de unión a semaforina-4d para el tratamiento del síndrome de rett. |
| JPWO2022137964A1 (ja) * | 2020-12-23 | 2022-06-30 | ||
| WO2023048726A1 (en) * | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| EP4692124A1 (en) * | 2023-04-03 | 2026-02-11 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
| CN117924494B (zh) * | 2024-01-23 | 2025-02-25 | 首都医科大学附属北京积水潭医院 | 特异性结合sema4d的抗原结合蛋白及其应用 |
| WO2026030311A1 (en) * | 2024-07-29 | 2026-02-05 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules to treat cognitive impairment |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN100480269C (zh) | 1997-04-07 | 2009-04-22 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| WO2002102973A2 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| US20050186208A1 (en) | 2003-05-30 | 2005-08-25 | Genentech, Inc. | Treatment with anti-VEGF antibodies |
| CN1922208A (zh) | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c－met二聚化及活化的方法和组合物 |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| WO2006110594A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| PT2427212T (pt) * | 2009-05-08 | 2017-11-20 | Vaccinex Inc | Anticorpos anti-cd100 e métodos para utilização dos mesmos |
| EP2429585B1 (en) | 2009-05-15 | 2018-04-18 | IRX Therapeutics, Inc. | Vaccine immunotherapy |
| CA2802376A1 (en) | 2010-06-14 | 2011-12-22 | Vaccinex, Inc. | Anti-vegf antibodies and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| WO2013055922A1 (en) * | 2011-10-11 | 2013-04-18 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6611709B2 (ja) | 2013-06-25 | 2019-11-27 | バクシネックス インコーポレーティッド | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| SG11201808554TA (en) | 2016-04-22 | 2018-11-29 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| US20190383836A1 (en) | 2017-02-22 | 2019-12-19 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2014
- 2014-09-11 NZ NZ630892A patent/NZ630892A/en unknown
- 2014-10-21 KR KR1020217030075A patent/KR20210118246A/ko not_active Ceased
- 2014-10-21 JP JP2016524999A patent/JP6461944B2/ja active Active
- 2014-10-21 PL PL14855074T patent/PL3060252T3/pl unknown
- 2014-10-21 CN CN201480070232.2A patent/CN106029093B/zh active Active
- 2014-10-21 KR KR1020167013445A patent/KR102308493B1/ko active Active
- 2014-10-21 IL IL275720A patent/IL275720B/en unknown
- 2014-10-21 DK DK14855074.2T patent/DK3060252T3/da active
- 2014-10-21 ES ES14855074T patent/ES2773961T3/es active Active
- 2014-10-21 WO PCT/US2014/061592 patent/WO2015061330A1/en not_active Ceased
- 2014-10-21 IL IL295045A patent/IL295045B2/en unknown
- 2014-10-21 CA CA2927841A patent/CA2927841C/en active Active
- 2014-10-21 MX MX2016005050A patent/MX374708B/es active IP Right Grant
- 2014-10-21 BR BR112016009047-0A patent/BR112016009047B1/pt active IP Right Grant
- 2014-10-21 EP EP19208515.7A patent/EP3639853B1/en active Active
- 2014-10-21 CA CA3193983A patent/CA3193983A1/en active Pending
- 2014-10-21 EP EP14855074.2A patent/EP3060252B1/en active Active
- 2014-10-21 PT PT148550742T patent/PT3060252T/pt unknown
- 2014-10-21 SG SG11201603167YA patent/SG11201603167YA/en unknown
- 2014-10-21 KR KR1020227025504A patent/KR102602502B1/ko active Active
- 2014-10-21 AU AU2014340210A patent/AU2014340210B2/en active Active
- 2014-10-21 US US14/519,965 patent/US9598495B2/en active Active
- 2014-10-21 CN CN202310282388.8A patent/CN116966293A/zh active Pending
- 2014-10-21 KR KR1020237038769A patent/KR20230159633A/ko not_active Ceased
- 2014-10-21 SG SG10201707786QA patent/SG10201707786QA/en unknown
- 2014-10-21 EA EA201690813A patent/EA033072B1/ru unknown
-
2015
- 2015-06-29 US US14/753,882 patent/US9249227B2/en active Active
-
2016
- 2016-04-13 IL IL245089A patent/IL245089B/en active IP Right Grant
- 2016-04-19 MX MX2020009260A patent/MX2020009260A/es unknown
- 2016-04-19 ZA ZA201602686A patent/ZA201602686B/en unknown
-
2017
- 2017-03-21 US US15/465,509 patent/US10385136B2/en active Active
-
2018
- 2018-12-26 JP JP2018241924A patent/JP6875363B2/ja active Active
-
2019
- 2019-07-02 US US16/460,593 patent/US10800853B2/en active Active
- 2019-10-28 AU AU2019257379A patent/AU2019257379B2/en active Active
-
2021
- 2021-04-06 AU AU2021202095A patent/AU2021202095B9/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019059786A5 (ja) | ||
| JP2020180158A5 (ja) | ||
| JP2020500525A5 (ja) | ||
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2015530971A5 (ja) | ||
| JP2010526028A5 (ja) | ||
| JP2010539921A5 (ja) | ||
| JP2018530331A5 (ja) | ||
| JP2010521147A5 (ja) | ||
| JP2009225799A5 (ja) | ||
| JP2010506596A5 (ja) | ||
| JP2020536532A5 (ja) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| IL275720B (en) | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders | |
| JP2018193386A5 (ja) | ||
| JP2011528561A5 (ja) | ||
| JP2014508748A5 (ja) | ||
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| RU2021124437A (ru) | Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования | |
| JP2017502920A5 (ja) | ||
| RU2013141134A (ru) | Антитела, которые специфично связывают альфа-токсин staphylococcus aureus, и способы их применения | |
| JP2017113019A5 (ja) | ||
| JP2015508757A5 (ja) | ||
| JP2013506428A5 (ja) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение |